Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407314 · ClinicalTrials.gov registry record · Phase 4
Ticagrelor and Peripheral Arterial Disease
A Phase 4 study, sponsored by Arkansas Heart Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT02407314 is a Phase 4 study that was terminated before completion, run by Arkansas Heart Hospital. The registered enrollment target is 26 participants.
The verdict
NCT02407314, a Phase 4 study, was terminated before completion, sponsored by Arkansas Heart Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting.
Interventions
- DRUG Aspirin
- DEVICE Optical Coherence Tomography
- PROCEDURE Percutaneous Peripheral Intervention
- OTHER Ankle Brachial Index
- OTHER Six minute walk distance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-06 |
| Est. Completion | 2017-01-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02407314
The ClinicalTrials.gov registry entry for NCT02407314 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arkansas Heart Hospital, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aspirin is the first listed.
NCT02407314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02407314 about?
NCT02407314 is a clinical study titled "Ticagrelor and Peripheral Arterial Disease". This is an interventional study assessing the effectiveness of Ticagrelor on the reduction of thrombus burden using optical coherence tomography in patients undergoing peripheral artery stenting.
What is the current status of trial NCT02407314?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2015-06. Estimated completion is 2017-01-17.
What interventions are being tested in trial NCT02407314?
The interventions under investigation include: Aspirin (DRUG), Optical Coherence Tomography (DEVICE), Percutaneous Peripheral Intervention (PROCEDURE), Ankle Brachial Index (OTHER), Six minute walk distance (OTHER).
Who is sponsoring clinical trial NCT02407314?
This trial is sponsored by Arkansas Heart Hospital, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.